Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration

Koureta, Evgenia; Cholongitas, Evangelos

doi:10.3389/fphar.2024.1343587

Cited by 4 publications

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A viable therapeutic option for the treatment of MAFLD is the antidiabetic drug semaglutide, which is available on the market either as a subcutaneous injection or as an oral drug [55]. Semaglutide is an agonist of the GLP-1 receptor which, when binding to the GLP-1 receptor, triggers various signaling mechanisms that lead to insulin secretion and a reduction in glucagon, which in turn results in a reduction in blood glucose levels [56]. This drug is also approved for the treatment of obesity, as it can promote weight loss by regulating appetite and inhibiting gastric emptying [56,57].…”

Section: Incretin and Glucagon Receptor Agonistsmentioning

confidence: 99%

“…Semaglutide is an agonist of the GLP-1 receptor which, when binding to the GLP-1 receptor, triggers various signaling mechanisms that lead to insulin secretion and a reduction in glucagon, which in turn results in a reduction in blood glucose levels [56]. This drug is also approved for the treatment of obesity, as it can promote weight loss by regulating appetite and inhibiting gastric emptying [56,57]. Last year, a meta-analysis by Zhu et al reported that semaglutide significantly reduced hepatic steatosis, inflammation, hepatocellular ballooning and liver stiffness, while the effect on reducing fibrosis stage is still uncertain [58].…”

Section: Incretin and Glucagon Receptor Agonistsmentioning

confidence: 99%

See 1 more Smart Citation

MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development

Khaznadar,

Petrovic

et al. 2024

CIMB

View full text Add to dashboard Cite

With around one billion of the world’s population affected, the era of the metabolic-associated fatty liver disease (MAFLD) pandemic has entered the global stage. MAFLD is a chronic progressive liver disease with accompanying metabolic disorders such as type 2 diabetes mellitus and obesity which can progress asymptomatically to liver cirrhosis and subsequently to hepatocellular carcinoma (HCC), and for which to date there are almost no approved pharmacologic options. Because MAFLD has a very complex etiology and it also affects extrahepatic organs, a multidisciplinary approach is required when it comes to finding an effective and safe active substance for MAFLD treatment. The optimal drug for MAFLD should diminish steatosis, fibrosis and inflammation in the liver, and the winner for MAFLD drug authorisation seems to be the one that significantly improves liver histology. Saroglitazar (Lipaglyn®) was approved for metabolic-dysfunction-associated steatohepatitis (MASH) in India in 2020; however, the drug is still being investigated in other countries. Although the pharmaceutical industry is still lagging behind in developing an approved pharmacologic therapy for MAFLD, research has recently intensified and many molecules which are in the final stages of clinical trials are expected to be approved in the coming few years. Already this year, the first drug (Rezdiffra™) in the United States was approved via accelerated procedure for treatment of MAFLD, i.e., of MASH in adults. This review underscores the most recent information related to the development of drugs for MAFLD treatment, focusing on the molecules that have come furthest towards approval.

show abstract

Section: Incretin and Glucagon Receptor Agonistsmentioning

confidence: 99%

Section: Incretin and Glucagon Receptor Agonistsmentioning

confidence: 99%

MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development

Khaznadar,

Petrovic

et al. 2024

CIMB

View full text Add to dashboard Cite

show abstract

Dawn of an era of effective treatments for MAFLD

Gofton,

George

2024

Portal Hypertension & Cirrhosis

View full text Add to dashboard Cite

Fatty liver disease is a commonly occurring disease resulting in hepatic and extrahepatic complications. To date, there have been few available treatments beyond conventional lifestyle modification. While lifestyle modifications resulting in weight loss >10% have shown to be beneficial for metabolic dysfunction‐associated steatohepatitis (MASH), for the majority of patients, this is difficult to achieve. The recent approval of resmetirom (a thyroid hormone receptor beta agonist) by the Food and Drug Administration following positive results for histological outcomes in a phase 3 trial has opened the door for new treatments for metabolic (dysfunction)‐associated fatty liver disease (MAFLD) and MASH. There are currently a number of phase 3 trials targeting a variety of signaling pathways involved in the pathogenesis of metabolic steatohepatitis that are also promising. This review focuses on the currently available treatments for MAFLD and MASH, ongoing phase 3 clinical trials, and unresolved controversies in clinical trials in this area.

show abstract

Research Progress on the Clinical Application of GLP-1RA Drug Semaglutide

陈

2024

ACM

View full text Add to dashboard Cite

Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration

Cited by 4 publications

References 52 publications

MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development

MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development

Dawn of an era of effective treatments for MAFLD

Research Progress on the Clinical Application of GLP-1RA Drug Semaglutide

Contact Info

Product

Resources

About